Literature DB >> 9989628

Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy.

B Becher1, P S Giacomini, D Pelletier, E McCrea, A Prat, J P Antel.   

Abstract

Interferon-gamma (IFN-gamma) is implicated as a participant in the immune effector and regulatory mechanisms considered to mediate the pathogenesis of multiple sclerosis (MS). We have used an intracellular cytokine staining technique to demonstrate that the proportion of ex vivo peripheral blood CD4 and CD8 T-cell subsets expressing IFN-gamma is increased in secondary progressing (SP) MS patients, whereas the values in untreated relapsing-remitting (RR) MS patients are reduced compared with those of controls. Patients treated with interferon-beta (IFN-beta) have an even more significant reduction in the percentage of IFN-gamma-secreting cells. The finding that the number of IFN-gamma-expressing CD8 cells is increased in SPMS patients, a group with reduced functional suppressor activity, and is most significantly reduced by IFN-beta therapy, which increases suppressor activity, indicates that IFN-gamma secretion by CD8 T cells and functional suppressor defects attributed to this cell subset in MS can be dissociated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989628

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  17 in total

Review 1.  Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.

Authors:  Xiao-Fang Liu; Yue-Bei Luo; Zhao-Hui Luo; Huan Yang
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

Review 2.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

Review 3.  Stage-specific immune dysregulation in multiple sclerosis.

Authors:  Benjamin M Segal
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

4.  Interferon beta1a treatment modulates TH1 expression in gammadelta + T cells from relapsing-remitting multiple sclerosis patients.

Authors:  C L Elliott; S Y El-Touny; M L Filipi; K M Healey; M P Leuschen
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

5.  A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis.

Authors:  Nathalie Arbour; Andreas Holz; Jack C Sipe; Denise Naniche; John S Romine; Jack Zyroff; Michael B A Oldstone
Journal:  J Neuroimmunol       Date:  2003-04       Impact factor: 3.478

6.  Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response.

Authors:  Jerome J Graber; David Ford; Min Zhan; Gordon Francis; Hillel Panitch; Suhayl Dhib-Jalbut
Journal:  J Neuroimmunol       Date:  2007-02-27       Impact factor: 3.478

7.  Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.

Authors:  Nitin J Karandikar; Michael P Crawford; Xiao Yan; Robert B Ratts; Jason M Brenchley; David R Ambrozak; Amy E Lovett-Racke; Elliot M Frohman; Peter Stastny; Daniel C Douek; Richard A Koup; Michael K Racke
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

8.  Beneficial effect of co-polymer 1 on cytokine production by CD4 T cells in multiple sclerosis.

Authors:  B Fellay; M Chofflon; C Juillard; A M Paunier; T Landis; S Roth; M L Gougeon
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

9.  Circulating lymphocyte subsets linked to intracellular cytokine profiles in normal humans.

Authors:  M Matsui; S Araya; H-Y Wang; N Onai; K Matsushima; T Saida
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

Review 10.  The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.

Authors:  Caterina Veroni; Francesca Aloisi
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.